Makaleler
Tümü (19)
SCI-E, SSCI, AHCI (15)
SCI-E, SSCI, AHCI, ESCI (17)
ESCI (2)
Scopus (18)
TRDizin (2)
2025
20251. Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis
ÇETİN T. E., SÜTCÜOĞLU O., AKDOĞAN O., SAVAŞ G., Günel N., ÜNER A., et al.
BMC Cancer
, cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)
2025
20252. Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study)
Onur İ. D., Özdemir P. A., AKDOĞAN O., Başkurt K., Kara M. I., Kalkan D. Ö., et al.
Supportive Care in Cancer
, cilt.33, sa.12, 2025 (SCI-Expanded, Scopus)
2025
20253. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study
Efil S. C., Bilgin B., Bilgetekin I., Helvaci K., Sakalar T., Nayir E., et al.
Scientific Reports
, cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)
2025
20254. Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey
AKDOĞAN O.
Journal of Cancer Policy
, cilt.45, 2025 (ESCI, Scopus)
2025
20255. Rezeksiyon Edilmiş Uterin Karsinosarkom Tanılı Hastalarda Prognostik Bir Gösterge Olarak Tanı Anındaki Menopozal Durum
Bolek H., Yalçıner M., sekmek s., CEYLAN F., akdogan o., UNCU D., et al.
Ankara Üniversitesi Tıp Fakültesi Mecmuası
, cilt.78, sa.2, ss.120-127, 2025 (TRDizin)
2025
20256. Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
Hacioglu M. B., Kucukarda A., Gokmen I., Gurbuz A. F., Araz M., Kahvecioglu F. A., et al.
Prostate
, cilt.85, sa.7, ss.693-702, 2025 (SCI-Expanded, Scopus)
2025
20257. Assessment of the CALLY Index, a Novel Immunonutrivite Marker, in Perioperatively Treated Gastric Cancer Patients Perioperatif Tedavi Görmüş Mide Kanseri Hastalarında Yeni Bir İmmünonutrisyonel Belirteç Olarak CALLY İndeksi Değerlendirilmesi
AKDOĞAN O., Yücel K. B., YAZICI O., ÖZET A., ÖZDEMİR N.
Gazi Medical Journal
, cilt.36, sa.1, ss.85-90, 2025 (ESCI, Scopus)
2024
20248. Impact of Serum GDF-15 and IL-6 on Immunotherapy Response in Cancer: A Prospective Study
AKDOĞAN O., TÜRKMEN S., Uyar G. C., Yucel K. B., TÜFEKÇİ B., GÜRLER F., et al.
CANCERS
, cilt.16, sa.24, 2024 (SCI-Expanded, Scopus)
2024
20249. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center
Barlas T., Sutcuoglu O., Akdogan O., Balos Toruner F. S., Akturk M. Y., Özdemir N., et al.
ENDOCRINE-RELATED CANCER
, cilt.31, sa.11, 2024 (SCI-Expanded, Scopus)
2024
202410. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study
Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.
CANCERS
, cilt.16, sa.18, 2024 (SCI-Expanded, Scopus)
2024
202411. The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer
Akdogan O., Ogut B., Sutcuoglu O., Sert A., Gurler F., Akyurek N., et al.
BMC CANCER
, cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)
2024
202412. Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms
Gürler F., Aktürk Esen S., Kurt İnci B., Sütçüoğlu O., Uçar G., Akdoğan O., et al.
CANCER INVESTIGATION
, cilt.42, sa.2, ss.141-154, 2024 (SCI-Expanded, Scopus)
2023
202313. Correspondence: Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer
AKDOĞAN O., SÜTCÜOĞLU O., ÖZET A., YAZICI O., ÖZDEMİR N.
Supportive Care in Cancer
, cilt.31, sa.8, 2023 (SCI-Expanded, Scopus)
2023
202314. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective
SÜTCÜOĞLU O., ERDAL Z. S., Akdoğan O., ÇELTİKÇİ E., ÖZDEMİR N., ÖZET A., et al.
Turkish Journal of Medical Sciences
, cilt.53, sa.1, ss.420-431, 2023 (SCI-Expanded, Scopus, TRDizin)
2022
202215. Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer
AKDOĞAN O., Sutcuoglu O., Ogut B., Akyurek N., Ozdemir N., Ozet A., et al.
IMMUNOTHERAPY
, cilt.14, sa.14, ss.1121-1131, 2022 (SCI-Expanded, Scopus)
2021
202116. Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists
Suticen E., Atas N., AVANOĞLU GÜLER A., AKDOĞAN O., Babaoglu H., SATIŞ H., et al.
CLINICAL RHEUMATOLOGY
, cilt.40, sa.7, ss.2865-2871, 2021 (SCI-Expanded, Scopus)
2021
202117. The role of serum albumin/globulin ratio in combination with prognostic risk indexes of febrile neutropenia
Sütcüoğlu O., Akdoğan O., Gürler F., Kurt İnci B., Özdemir N., Özet A., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
, cilt.75, sa.7, 2021 (SCI-Expanded, Scopus)
2020
202018. Comment on: Inpatient epidemiology and economic burden of granulomatosis with polyangiitis: a 10-year study of the national inpatient sample
Satis H., Kayahan N., Babaoglu H., Akdogan O., YAPAR D.
RHEUMATOLOGY
, cilt.59, sa.12, 2020 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. Prospective observational study to assess the prophylactic effect of topical diclofenac in preventing the development of hand foot syndrome in patients with colorectal and gastric cancer on capecitabine therapy
Yazıcı O., Akdoğan O., Eryildiz Yucel S., Bir Yücel K., Gürler F., Özet A., et al.
ESMO CONGRESS 2024 , Barcelona, İspanya, 13 - 17 Eylül 2024, ss.13, (Özet Bildiri)
2024
20242. Assessing Mortality Rates Within 30 Days Following the Last Dose of Immunotherapy A MultiCenter Retrospective Study
BAŞKURT K., AKDOĞAN O., KARATEKE Y. S., DELİKTAŞ ONUR İ., YAZICI O., YILDIZ B., et al.
ESMO CONGRESS 2024, Barcelona, İspanya, 13 - 17 Eylül 2024, (Özet Bildiri)
2024
20243. İmmün kontrol noktası inhibitörlerine bağlı endokrinolojik yan etkiler ile kemokin ve sitokin düzeylerinin öngördürücü rolü: Prospektif çalışma
Barlas T., Sütcüoğlu O., Akdoğan O., Törüner F. S., Aktürk M. Y., Özdemir N., et al.
45. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Antalya, Türkiye, 17 - 20 Ekim 2024, ss.100, (Tam Metin Bildiri)
2020
20204. NÖTROPENİK ATEŞ İLEBAŞVURAN HASTADAGÜNCEL RİSK İNDEKSLERİYETERLİ Mİ?
SÜTCÜOĞLU O., AKDOĞAN O., GÜRLER F., KURT İNCİ B., ÖZDEMİR N., YAZICI O.
TTOD Sanal Kongresi, Türkiye, 12 - 15 Kasım 2020, (Özet Bildiri)